Abstract
Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.
Original language | English |
---|---|
Pages (from-to) | 55-57 |
Number of pages | 3 |
Journal | Sarcoidosis Vasculitis and Diffuse Lung Diseases |
Volume | 29 |
Issue number | 1 |
Publication status | Published - 2012 |
Keywords
- 18F-FDG-PET
- Infliximab
- Sarcoidosis
- TNF-α mAb